Takeda Zasocitinib Beats Sotyktu in Head-to-Head Phase 3; Summit Pulls $500M Offering

FDA greenlights Merck's Welireg-Keytruda combo for adjuvant kidney cancer — and the study beat active Keytruda monotherapy, not placebo.

Jazz's Zepzelca fails its confirmatory Phase 3 in second-line small cell lung, Amgen brings Duke into its Tavneos fight with the FDA, and Incyte writes a one-point-two-five billion dollar check for Vega Therapeutics.

Welcome to The Pharma Closeout for Friday, June twelfth, twenty twenty-six. I'm Alex Mercer.

And I'm Maya Patel. Let's get to it.

The FDA today approved Merck's combination of Welireg — belzutifan — with Keytruda as adjuvant treatment for clear cell renal cell carcinoma. The approval, granted under priority review, also covers the subcutaneous formulation Keytruda Qlex. The Phase 3 LITESPARK-022 trial enrolled a substantial patient population post-nephrectomy with intermediate-high or high risk of recurrence, or resected metastases with no evidence of disease. The combination demonstrated a meaningful reduction in recurrence or death risk compared to Keytruda alone.

The comparator is what makes this noteworthy. This wasn't belzutifan-Keytruda against placebo — the control arm was active Keytruda monotherapy, which already has a track record in adjuvant RCC. Showing meaningful additional risk reduction by layering HIF-2-alpha inhibition onto an efficacious PD-1 backbone represents a substantially higher bar than a placebo-controlled design. It means the incremental benefit of belzutifan had to be large enough to register on top of a drug that was already moving the needle. That's a genuinely demanding evidentiary standard, and clearing it says something about the biological rationale for dual-pathway blockade in this setting.

For Merck, every combination label matters right now. The Keytruda franchise is approaching exclusivity loss, and stacking new indications is the clearest path to extending commercial life. Each new label doesn't just add volume — it adds switching costs for payers and prescribers who now have to manage formulary transitions across a broader set of tumor types. Worth noting — Merck finished the session with modest downward movement. The market isn't rewarding label extensions at this stage of the cycle.

Because the gap investors are pricing isn't whether Keytruda can accumulate more indications — it's whether Merck has a successor franchise that can absorb the revenue hit when exclusivity goes. A strong adjuvant RCC combination is clinically rigorous and commercially incremental. Those are different things. And right now the Street is overwhelmingly focused on the latter question. You can win every label expansion battle and still lose the franchise transition war — that's the overhang the stock is carrying, and one more approval doesn't lift it.

Which frames the strategic logic for belzutifan specifically. If belzutifan can demonstrate activity across multiple Keytruda combination settings, it starts to look less like a single-indication asset and more like the anchor of a next-generation combo platform. That's the longer game Merck is playing here — whether the market is willing to credit it yet is a separate question.

Shifting to the deal and pipeline roundup — the data that may draw a sharper market reaction today came out of Jazz Pharmaceuticals. The Phase 3 LAGOON trial evaluating Zepzelca — lurbinectedin — in second-line small cell lung cancer did not meet its primary endpoint of overall survival. Zepzelca monotherapy trailed control in median overall survival, demonstrating a numerically unfavorable hazard ratio. The combination arm with irinotecan showed a favorable trend in median survival but failed to achieve statistical significance.

The trial design tells you why. LAGOON enrolled patients with a history of CNS involvement — a population the Phase 2 pivotal that supported accelerated approval explicitly excluded. In that CNS subgroup, monotherapy showed a substantially elevated hazard ratio. Strip those patients out and monotherapy shows a less favorable profile against a control arm that outperformed historical benchmarks. A broader enrollment didn't prove the drug fails in second line — it proved the efficacy signal is narrower than the enrollment criteria assumed. That distinction matters because it shapes whether the agency pursues a label revision or a full withdrawal.

And that distinction is exactly what Jazz is going to try to operationalize in its FDA discussions. If you can credibly argue the drug works in a definable patient subset but not in the broader population enrolled in LAGOON, you're making the case for a refined label rather than a rescinded one. The challenge is that the accelerated approval pathway doesn't come with a lot of patience for post-hoc subgroup rationalizations — the confirmatory trial is supposed to be definitive.

Right. And regulators have gotten more skeptical of that move, not less. The agency has been publicly signaling a lower tolerance for accelerated approvals that can't convert. So Jazz is swimming against the current here, regardless of how sound the subgroup argument is scientifically. The optics of presenting a failed confirmatory trial and then asking for a narrower label — that's a tough conversation to walk into.

Jazz moved quickly to separate this from the IMforte story. The first-line maintenance approval rests on that Phase 3, which demonstrated meaningful reductions in both progression risk and mortality versus atezolizumab maintenance alone. LAGOON's failure specifically puts the second-line accelerated approval at risk. Jazz is in discussions with the agency and held its twenty twenty-six guidance unchanged.

First-line maintenance is where commercial volume concentrates in extensive-stage disease — that's the label protecting the revenue base. Losing second-line would sting but it's survivable. What's harder to manage is the optics: a confirmatory trial failure, a potential withdrawal, and an FDA conversation now entirely on the agency's terms. When you're the company that has to ask to keep a label rather than the company presenting data that earns one, the power dynamic shifts fundamentally.

On the deal side, Incyte agreed to acquire Vega Therapeutics — a subsidiary of Star Therapeutics — for one-point-two-five billion dollars. Let's bring in Marcus Webb for this one.

Name the pattern: three major transactions in a single week, all at full-stretch valuations. That stops being individual deal stories and starts being a signal about how urgently the industry needs to reload before the next wave of exclusivity losses hits. The question isn't whether any single deal was overpriced — it's whether the entire market for clinical-stage assets has repriced upward permanently because the demand side is structural, not cyclical. Every large-cap pharma is looking at the same patent cliffs, and the math forces their hand.

The financing markets echo that urgency. Enliven Therapeutics priced a significant offering at a strong share price, notably upsized from its initial fundraising target. BioPharma Dive noted Enliven presented data positioning a kinase inhibitor against a Merck leukemia program, which helps explain why institutions drove significant demand well above the original fundraising target. When you can position your asset directly against an incumbent franchise from a top-five pharma, institutional capital reads that as a de-risked competitive thesis — and prices accordingly.

Also worth noting on the regulatory side — the Amgen-FDA standoff over Tavneos escalated today. Amgen announced it will file a third-party review of Tavneos data, conducted by Duke's Clinical Research Institute, ahead of a formal FDA hearing, with submission planned for the coming weeks.

The backdrop makes this confrontation unusually pointed. The FDA has recommended withdrawing Tavneos' approval in ANCA-associated vasculitis. Amgen requested a hearing and is now building its case — due June twenty-ninth — while the drug posted strong Q1 sales with double-digit growth year over year, driven significantly by volume expansion, per Amgen's latest earnings. A drug gaining commercial momentum while the agency challenges its evidentiary basis — that is the tension defining this story. Every quarter that Tavneos grows makes the withdrawal calculus more complex, because you're no longer pulling a marginal product — you're disrupting an active treatment paradigm with real patient volume behind it.

Amgen's public letter framed this around limited treatment options and patient experience on therapy. That's calculated — it raises the political cost of withdrawal by centering access. Whether a Duke reanalysis actually shifts the agency's scientific position is genuinely uncertain. But it changes the dynamics of the hearing — it's one thing for the FDA to override its own prior approval, and a different thing entirely to do it over an independent academic reanalysis of the same data. The Duke name carries weight precisely because it's not Amgen's internal statisticians making the argument. If an independent academic center reviews the same dataset and reaches a different conclusion than the FDA's reviewers, the hearing panel has to grapple with that disagreement publicly. That's the strategic value — it doesn't guarantee a win, but it forces the agency to defend its position against a credible counterparty, not just against the sponsor.

Two more approvals today. AstraZeneca's Truqap — capivasertib — received FDA approval in combination with abiraterone for PTEN-deficient metastatic hormone-sensitive prostate cancer, per AstraZeneca's announcement. And Sanofi's Tzield received accelerated approval for patients recently diagnosed with stage 3 type 1 diabetes, extending the label beyond its existing stage 2 indication.

Truqap carves out a biomarker-selected lane in a large tumor population — PTEN loss runs through a significant fraction of mHSPC, so this isn't a narrow play. It's a precision oncology label in a volume indication, which is commercially the best of both worlds — you get the targeting story that justifies premium pricing and the addressable population that justifies the investment. On the policy side, CMS proposed a rule today that would codify the IRA's Medicare drug price negotiations, making them substantially harder for a future administration to unwind. Drug manufacturers as a subsector finished modestly down on the session. If that rule finalizes, the negotiation framework becomes structural — not policy that shifts with administrations, but codified process that persists regardless of who holds the White House. That's the kind of regulatory permanence that forces every long-range commercial model in the industry to incorporate pricing compression as a baseline assumption, not a downside scenario.

Looking ahead. Amgen's June twenty-ninth Tavneos submission is the nearest regulatory flashpoint. Kardigan, the cardiovascular drug developer, set IPO terms this week, targeting a substantial valuation in the biotech space. WuXi AppTec filed suit against the Pentagon in the D.C. federal court, challenging its placement on a Chinese military-linked companies list and calling the designation arbitrary and the product of political pressure. And Novo Nordisk's oral semaglutide picked up UK regulatory approval today, widening the oral GLP-1 footprint in another major market.

The WuXi case is the structural story. If a federal court finds the Pentagon's designation process lacked due process, the legal foundation for restricting Chinese CDMOs under BIOSECURE gets reexamined wholesale. Every company with WuXi in the supply chain is watching that docket — and the precedent could reset how this industry manages geopolitical manufacturing risk for years.

That's your Pharma Closeout for Friday, June twelfth. Merck's adjuvant kidney cancer approval, Jazz's Zepzelca setback in the LAGOON trial, Amgen drafting Duke into the Tavneos fight, Incyte's billion-dollar move for Vega Therapeutics, AstraZeneca opening a PTEN lane in prostate cancer, and the CMS proposal that could harden the IRA pricing framework. This industry does not take Fridays off. If this briefing saves you time, follow us on Spotify and drop a rating — we'll be back Sunday with the full week in review.

Go enjoy your weekend. We'll see you Sunday. ## EPISODE METADATA **Title:** FDA Approves Merck Welireg-Keytruda for Kidney Cancer; Jazz Zepzelca Phase 3 Fails; Incyte's $1.25B Vega Deal | Jun 12, 2026 **Description:** FDA approves Merck's Welireg-Keytruda combo for adjuvant kidney cancer — 28% risk reduction vs. active Keytruda monotherapy in LITESPARK-022. Jazz's Zepzelca misses OS endpoint in Phase 3 LAGOON, Incyte acquires Vega Therapeutics for $1.25B, and Amgen files independent Duke review to fight FDA's proposed Tavneos withdrawal. **Tags:** Merck, Keytruda, Welireg, belzutifan, pembrolizumab, kidney cancer, renal cell carcinoma, LITESPARK-022, Jazz Pharmaceuticals, Zepzelca, lurbinectedin, small cell lung cancer, LAGOON, Incyte, Vega Therapeutics, Star Therapeutics, Amgen, Tavneos, avacopan, AstraZeneca, Truqap, capivasertib, prostate cancer, Sanofi, Tzield, type 1 diabetes, Enliven Therapeutics, WuXi AppTec, CMS, Medicare, IRA, Novo Nordisk, oral semaglutide, FDA, drug approvals, clinical trials, pharma, pharmaceutical, biotech, M&A #